2023-08-08 16:21:06 ET
- Atara Biotherapeutics press release ( NASDAQ: ATRA ): Q2 GAAP EPS of -$0.68 misses by $0.01 .
- Revenue of $0.96M (-98.1% Y/Y) misses by $2.81M .
- Cash, cash equivalents and short-term investments as of June 30, 2023, totaled $153.6 million, as compared to $205.4 million as of March 31, 2023.
- Net cash used in operating activities was $52.8 million for the second quarter 2023, as compared to $64.0 million in the same period in 2022.
- Atara believes that its cash and investments as of June 30, 2023, will be sufficient to fund the Company’s planned operations into second quarter 2024.
For further details see:
Atara Biotherapeutics GAAP EPS of -$0.68 misses by $0.01, revenue of $0.96M misses by $2.81M